Advertisement

Cutaneous Manifestations

  • Luciano Alessandroni
  • Andrea Scotti
Part of the Updates in Surgery book series (UPDATESSURG)

Abstract

Cutaneous lesions are well-recognized extraintestinal manifestations of inflammatory bowel disease (IBD), specifically. Crohn’s disease (CD) and ulcerative colitis (UC). These extraintestinal manifestations, associated with intestinal symptoms, contribute to the impaired quality of life of patients with CD. During the course of the disease, a great variety of cutaneous lesions may develop, many of which are secondary to granulomatous cutaneous disease, reactive skin eruptions, undernourishment, pharmacological treatment, and other associated conditions [1]. The occurrence of these manifestations varies widely but the mean incidence is around 10% [2]. The cutaneous abnormalities that accompany IBD can be viewed as a spectrum of changes resulting from leukocyte migration to different sites of the skin. Diagnosis of the cutaneous manifestations of CD is made on clinical grounds, based on their characteristics features, and the exclusion of other specific skin disorders; biopsy is rarely appropriate or necessary [3]. Whether the cutaneous manifestations can be considered as real extraintestinal patterns of CD or simply represent associations between different autoimmune diseases is still not clear.

Keywords

Inflammatory Bowel Disease Pyoderma Gangrenosum Cutaneous Manifestation Hidradenitis Suppurativa Erythema Nodosum 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Warner AS, MacDermott P (1996) Extraintestinal manifestations. In: Prantera C, Korelitz B (eds) Crohn’s disease Dekker, New York, pp 467–488Google Scholar
  2. 2.
    Ephgrave K (2007) Extraintestinal manifestations of Crohn’s disease. Surg Clin North Am 87:673–680CrossRefPubMedGoogle Scholar
  3. 3.
    Caprili R, Gassull MA, Escher JC et al (2006) European evidence based consensus on the diagnosis and management of Crohn’s disease: special situations. Gut 55(Suppl 1):i36–38CrossRefGoogle Scholar
  4. 4.
    Greenstein AJ, Janowitz HD, Sachar DB (1976) The extraintestinal complications of Crohn’s disease and ulcerative colitis. A study of 700 patients. Medicine 55:401–412CrossRefPubMedGoogle Scholar
  5. 5.
    Bernstein CN, Blanchard JF, Rawsthorne P, Yu N (2001) The prevalence of extraintestinal diseases in inflammatory bowel disease. A population based study. Am J Gastroenterol 96:1116–1122CrossRefPubMedGoogle Scholar
  6. 6.
    Freeman HJ (2005) Erythema nodosum and pyoderma gangerenosum in 50 patients with Crohn’s disease. Can J Gastroenterol 19:603–606PubMedGoogle Scholar
  7. 7.
    Farhi D, Cosnes J, Zizi N et al (2008) Significance of erhthema nodosum and pyoderma gangrenosum in inflammatory bowel diseases. Medicine 87:281–293CrossRefPubMedGoogle Scholar
  8. 8.
    Requena L, Yus E (2008) Erythema nodosum. Dermatol Clin 26:425–438CrossRefPubMedGoogle Scholar
  9. 9.
    Tavarela Veloso F (2004) Review article: skin complications associated with inflammatory bowel disease. Alimen Pharmacol Ther 220(Suppl 4):50–53CrossRefGoogle Scholar
  10. 10.
    Schwaegerle SM, Bergfeld WF, Snitzer D, Tidrick TR (1988) Pyoderma gangrenosum: a review. J Am Acad Dermatol 18:559–568CrossRefPubMedGoogle Scholar
  11. 11.
    Su WPD, Schroeter AL, Perry HO, Powell PC (1986) Histopathologic and immunopathologic study of pyoderma gangrenosum. J Cutan Pathol 13:223–230CrossRefGoogle Scholar
  12. 12.
    Wollina V (2002) Clinical management of pyoderma gangrenosum. Am J Clin Dermatol 3:14–58CrossRefGoogle Scholar
  13. 13.
    Ljung T, Staun M, Grove O et al (2002) Pyoderma gangrenosum associated with Crohn’s disease: effect of TNF alpha blockade with infliximab. Scand J Gastroenterol 37:1108–1110CrossRefPubMedGoogle Scholar
  14. 14.
    Regueiro M, Valentine J, Plevy S et al (2003) Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease. Am J Gastroenterol 98:1824–1826CrossRefGoogle Scholar
  15. 15.
    Brooklyn T, Dunnill GS, Shetty A et al (2006) Infliximab for the treatment of pyoderma gangrenosusm: a randomised, double-blind placebo-controlled trial. Gut 55:505–509CrossRefPubMedGoogle Scholar
  16. 16.
    Zold E, Nagy A, Devenyi K et al (2009) Successful use of adalimumab for treating fistulizing Crohn’s disease with pyoderma gangrenosum: two birds with one stone. World J Gastroenterol 15:2293–2295CrossRefPubMedGoogle Scholar
  17. 17.
    Cohen PR (2007) Sweet’s syndrome. A comprehensive review of an acute febrile neutrophilic dermatosis. Orph J Rare Dis 2:34–62CrossRefGoogle Scholar
  18. 18.
    Kemmett D, Hunter JA (1990) Sweet’s syndrome a clinicopathologic review of twenty-nine cases. J Am Acad Dermatol 23:503–507CrossRefPubMedGoogle Scholar
  19. 19.
    Ray TL, Levine JB, Weiss W, Ward PA (1982) Epidermiolysis bollosa acquisita and inflammatory bowel disease. J Am Acad Dermatol 6:242–252CrossRefPubMedGoogle Scholar
  20. 20.
    Komatsuda A, Kinoshita K, Togashi M et al (2008) Cutaneous polyrteritis nodosa in a patient with Crohn’s disease. Mod Reumathol 18:639–642CrossRefGoogle Scholar
  21. 21.
    Takahashi H, Hashimoto Y, Ishida-Yamamoto A et al (2007) Psoriasiform and pustular eruption induced by infliximab. J Dermatol 34:468–472CrossRefPubMedGoogle Scholar
  22. 22.
    Plauth M, Jensu H, Meyle G (1991) Oral manifestations of Crohn’s disease: an analysis of 79 cases. J Clin Gastroenterol 13:29–37CrossRefPubMedGoogle Scholar
  23. 23.
    Palamaras I, El-Jabbour J, Pietropaolo N et al (2008) Metastatic Crohn’s diesease: a review. J Eur Acad Dermatol Venereol 22:1033–1043CrossRefPubMedGoogle Scholar
  24. 24.
    Emanuel PO, Phelps G (2008) Metastatic Crohn’s disease: a histopathologic study of 12 cases. J Cutan Pathol 35:4657–4661Google Scholar
  25. 25.
    Konrad A, Seibold F (2003) Response of cutaneous Crohn’s disease to infliximab and methotrexate. Dig Liver Dis 35:351–356CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Italia 2010

Authors and Affiliations

  • Luciano Alessandroni
    • 1
  • Andrea Scotti
    • 1
  1. 1.Department of SurgerySan Camillo-Forlanini HospitalRomeItaly

Personalised recommendations